• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

26.48 +0.12 (+0.46%)
Streaming Delayed Price Updated: 10:05 AM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 Next >
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
September 24, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
August 26, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
August 21, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
August 05, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
July 22, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
July 15, 2025
From Harmony Biosciences
Via Business Wire
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
June 11, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
June 05, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​
May 06, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
April 29, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
April 08, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
April 03, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
March 24, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
March 21, 2025
From The Schall Law Firm
Via Business Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
March 04, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
February 25, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
February 19, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
February 18, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
January 13, 2025
From Harmony Biosciences
Via Business Wire
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
December 17, 2024
Via ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
December 16, 2024
Via ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
December 13, 2024
Via ACCESSWIRE
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
August 06, 2024
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
April 30, 2024
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
October 31, 2023
From Harmony Biosciences
Via GlobeNewswire
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
August 17, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
NASDAQ: HRMY Investor Alert: Investigation over Potential Wrongdoing at Harmony Biosciences Holdings, Inc.
August 17, 2023
San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc. 
Via SBWire
< Previous 1 2 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  243.41
-1.23 (-0.50%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap